Effect of ritodrine hydrochloride infusion on fetal movement with the use of a fetal movement acceleration measurement recorder (FMAM recorder).
FMAM recorder
fetal development
fetal movement
ritodrine hydrochloride
β-stimulant
Journal
The journal of obstetrics and gynaecology research
ISSN: 1447-0756
Titre abrégé: J Obstet Gynaecol Res
Pays: Australia
ID NLM: 9612761
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
revised:
23
10
2022
received:
23
04
2022
accepted:
13
11
2022
pubmed:
30
11
2022
medline:
11
2
2023
entrez:
29
11
2022
Statut:
ppublish
Résumé
To investigate the effect of ritodrine hydrochloride infusion on fetal movement. We gathered 20 pregnant women who received ritodrine hydrochloride infusion as the treated group, and 147 pregnant women who did not as the control group. All women recorded gross fetal movement with the fetal movement acceleration measurement recorder after 28 gestational weeks. The record was divided into epochs of 10 s, and the ratio of movement-positive epochs to all epochs was calculated as the fetal movement index. Furthermore, the mean duration and the mean number per hour of no-fetal movement period, where the fetus did not move for 5 min or more, were calculated as the indexes of no-fetal movement. All indexes were compared between the two groups at 28-31 and 32-35 gestational weeks. The fetal movement indexes (%) were 17.29 ± 7.46 (mean ± SD) in the control group and 13.65 ± 7.13 in the treated group at 28-31 weeks (p = 0.139). At 32-35 weeks, they were 14.55 ± 6.43 and 18.50 ± 5.33, respectively (p = 0.03). Similarly, the no-fetal movement indexes (min, times/h) were 15.03 ± 10.99 and 1.61 ± 0.88, and 18.70 ± 15.80 and 1.75 ± 0.96 (p = 0.824, and 0.673) at 28-31 weeks. At 32-35 weeks, they were 18.13 ± 10.88 and 1.95 ± 0.97, and 9.20 ± 5.51 and 1.14 ± 0.71, respectively (p = 0.003, and 0.003). Ritodrine hydrochloride infusion increased the fetal movement and decreased the no-fetal movement period at 32-35 weeks.
Substances chimiques
Ritodrine
I0Q6O6740J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
606-613Subventions
Organisme : Japan Society for the Promotion of Science
ID : 22K09627
Informations de copyright
© 2022 Japan Society of Obstetrics and Gynecology.
Références
Manning FA, Platt LD, Sipos L. Antepartum fetal evaluation: development of a fetal biophysical profile. Am J Oster Gynecol. 1980;136:787-95.
Kojak A, Miskovic B, Stenopeic M, et al. New scoring system for fetal neurobehavior assessed by three and four-dimensional sonography. J Perinat Med. 2008;36:73-81.
Ryo E, Nishihara K, Matsumoto S, Camata H. A new method for long-term home monitoring of fetal movement by pregnant women themselves. Med Eng Phys. 2012;34:566-72.
Nishihara K, Ohki N, Camata H, Ryo E, Horiuchi S. Automated software analysis of fetal movement recorded during a pregnant Woman's sleep at home. Plops One. 2015;10(6):e0130503.
Ryo E, Kamata H, Seto M, Morita M, Nagaya Y, Nishihara K, et al. Reference values for a fetal movement acceleration measurement recorder to count fetal movements. Pediatr Res. 2018;83:961-8.
Soma M, Konda A, Fujieda S, et al. Difference in ritodrine pharmacokinetics between singleton and twin pregnancies. Jpn J Clin Pharmacol Ther. 2013;44(5):389-94.
Canadian Preterm Labor Investigators Group. Treatment of preterm labor with the beta-adrenergic agonist ritodrine. N Engl J Med. 1992;327:308-12.
Hill WC. Risks and complications of tocolysis. Clin Obstet Gynecol. 1995;38(4):725-45.
Ryo E, Seto M, Yatsuki K, Morita M, Kamata H. Measurement of pulse wave velocity in fetal descending aorta with dual doppler method: a preliminary study. SN Compr Clin Med. 2021;3:1133-6.
Gagnon R, Campbell K, Hunse C, Patrick J. Patterns of human fetal heart rate accelerations from 26 weeks to term. Am J Obstet Gynecol. 1987;157:743-8.
Yonaga Y, Ryo E, Yatsuki K, et al. Effect of ritodrine hydrochloride oral administration on fetal movements-observation using the fetal movement acceleration measurement recorder (FMAM recorder). J Jpn Soc Perinat Neonatal Med. 2021;57:98-102.
Wolf HT, Huusom LD, Henriksen TB, Hegaard HK, Brok J, Pinborg A. Magnesium sulphate for fetal neuroprotection at imminent risk for preterm delivery: a systematic review with meta-analysis and trial sequential analysis. BJOG. 2020;127(10):1180-8.
Carlan SJ, O'Brien WF. The effect of magnesium sulfate on the biophysical profile of normal term fetuses. Obstet Gynecol. 1991;77(5):681-4.
Kino E, Ohhashi M, Kawagoe Y, et al. Impact of tocolysis-intent magnesium sulfate and beta-adrenergic agonists on perinatal brain damage in infants born between 28-36 weeks' gestation. J Obstet Gynaecol Res. 2020;46(10):2027-35.
Witter FR, Zimmerman AW, Reichmann JP, Connors SL. In utero beta 2 adrenergic agonist exposure and adverse neurophysiologic and behavioral outcomes. Am J Obstet Gynecol. 2009;201(6):553-9.
Chae J, Cho GJ, Min-Jeong O, et al. In utero exposure to ritodrine during pregnancy and risk of autism in their offspring until 8 years of age. Sci Rep. 2021;11(1):1146. https://doi.org/10.1038/s41598-020-80904-y
Slotkin TA, Baker FE, Dobbins SS, Eylers JP, Lappi SE, Seidler F. Prenatal terbutaline exposure in the rat: selective effects on development of noradrenergic projections to cerebellum. Brain Res Bull. 1989;23:263-5.
Slotkin TA, Seidler FJ. Terbutaline impairs the development of peripheral noradrenergic projections: potential implications for autism spectrum disorders and pharmacotherapy of preterm labor. Neurotoxicol Teratol. 2013;36:91-6.
Zerrate MC, Pletnikov M, Connors SL, et al. Neuroinflammation and behavioral abnormalities after neonatal terbutaline treatment in rats: implications for autism. J Pharmacol Exp Ther. 2007;322:16-22.
World Health Organization (WHO): WHO recommendations on interventions to improve preterm birth outcomes; 2015 [cited 2021 Dec 28]. Available from: https://www.who.int/reproductivehealth/publications/maternal_perinatal_health/preterm-birthguideline/en/
ACOG: Practice bulletin for management of preterm labor; 2016 [cited 2021 Dec 28]. Available from: https://www.acog.org/clinical/clinical-guidance/practice-bulletin/articles/2016/10/managementof-preterm-labor
New South Wales Ministry of Health (NSW Health): Guideline on maternity-Management of threatened preterm labour; 2020 [cited 2021 Dec 28]. Available from https://www1.health.nsw.gov.au/pds/ActivePDS_Documents/GL2020_009.pdf
PRAC recommends restricted use of short-acting beta-agonists in obstetric indications. European Medicines Agency's Pharmacovigilance Risk Assessment Committee 2013；53374094.
Simhan HN, Caritis SN. Prevention of preterm delivery. N Engl J Med. 2007;357:477-87.